Southern Medical Association (SMA) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to SMA policy. SMA is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Samuel E. Crockett Chair in Diabetes Research
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Director, Scientific Services
The following nurse planner, Alyce Kuklinski, NP, RN has no real or apparent conflicts of interest to report.Disclosure of Unlabeled Use
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.Disclaimer
This program is intended for endocrinologists, cardiologists, primary care physicians, hospitalists, physician assistants, nurse practitioners, pharmacists, certified diabetes educators, and other healthcare providers who care for patients with type 2 diabetes.
Southern Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Southern Medical Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
If you are interested in having us report ABIM MOC, please ensure the following information is provided within your Member Profile:
1.0 contact hour may be earned for successful completion of this activity.
This continuing nursing education activity was approved by the Alabama State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2018, through November 12, 2019:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes
Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence
Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.
CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.